JP2017537622A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537622A5 JP2017537622A5 JP2017529284A JP2017529284A JP2017537622A5 JP 2017537622 A5 JP2017537622 A5 JP 2017537622A5 JP 2017529284 A JP2017529284 A JP 2017529284A JP 2017529284 A JP2017529284 A JP 2017529284A JP 2017537622 A5 JP2017537622 A5 JP 2017537622A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- seq
- acid sequence
- domain
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086346P | 2014-12-02 | 2014-12-02 | |
| US62/086,346 | 2014-12-02 | ||
| PCT/US2015/063267 WO2016089916A1 (en) | 2014-12-02 | 2015-12-01 | Methods and compositons for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017537622A JP2017537622A (ja) | 2017-12-21 |
| JP2017537622A5 true JP2017537622A5 (2) | 2019-01-10 |
Family
ID=56078487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529284A Pending JP2017537622A (ja) | 2014-12-02 | 2015-12-01 | がんを治療するための方法及び組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9650428B2 (2) |
| EP (1) | EP3227317A4 (2) |
| JP (1) | JP2017537622A (2) |
| KR (1) | KR20180041087A (2) |
| CN (1) | CN107709353A (2) |
| AR (1) | AR102879A1 (2) |
| AU (1) | AU2015355084A1 (2) |
| BR (1) | BR112017011771A2 (2) |
| CA (1) | CA2969714A1 (2) |
| EA (1) | EA201791210A1 (2) |
| HK (1) | HK1251862A1 (2) |
| IL (1) | IL252610A0 (2) |
| MX (1) | MX2017007272A (2) |
| PH (1) | PH12017501031A1 (2) |
| SG (2) | SG10202103475XA (2) |
| TW (1) | TW201636425A (2) |
| UY (1) | UY36418A (2) |
| WO (1) | WO2016089916A1 (2) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2850093B1 (en) | 2012-01-27 | 2019-01-09 | The Board of Trustees of the Leland Stanford Junior University | Therapeutic il-13 polypeptides |
| IN2015KN00329A (2) | 2012-08-09 | 2015-07-10 | Univ Leland Stanford Junior | |
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| WO2015042705A1 (en) | 2013-09-24 | 2015-04-02 | Medicenna Biopharma Inc. | Interleukin-4 receptor-binding fusion proteins and uses thereof |
| SG10202103475XA (en) | 2014-12-02 | 2021-05-28 | Prospect Chartercare Rwmc Llc | Methods and compositons for treating cancer |
| FI3909972T3 (fi) | 2015-06-19 | 2024-05-03 | Sebastian Kobold | Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä |
| KR102011789B1 (ko) * | 2015-08-05 | 2019-08-19 | 주식회사 셀랩메드 | 키메라 항원 수용체 및 키메라 항원 수용체가 발현된 t 세포 |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| WO2018112266A1 (en) * | 2016-12-14 | 2018-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Il-13 superkine: immune cell targeting constructs and methods of use thereof |
| CN110612119B (zh) | 2017-02-07 | 2024-10-29 | 西雅图儿童医院（Dba西雅图儿童研究所） | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
| JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための組成物および方法 |
| WO2018195339A1 (en) | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| WO2019073299A1 (en) | 2017-10-10 | 2019-04-18 | Medicenna Therapeutics, Inc. | IL-4 FUSION FORMULATIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) TUMORS |
| WO2019100079A1 (en) * | 2017-11-20 | 2019-05-23 | Prospect CharterCare RWMC, LLC d/b/a Roger Williams Medical Center | Compositions for improving car-t cell functionality and user thereof |
| KR102752985B1 (ko) | 2017-12-20 | 2025-01-10 | 포세이다 테라퓨틱스, 인크. | Vcar 조성물 및 사용 방법 |
| JP7549303B2 (ja) | 2018-01-22 | 2024-09-11 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞の使用方法 |
| US11701405B2 (en) * | 2018-01-26 | 2023-07-18 | City Of Hope | Chimeric antigen receptors and methods for reducing toxicity |
| SG11202007426XA (en) | 2018-02-06 | 2020-09-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| CN110157674A (zh) * | 2018-02-12 | 2019-08-23 | 深圳宾德生物技术有限公司 | 一种靶向性t淋巴细胞及其制备方法和应用 |
| CN110144326A (zh) * | 2018-02-12 | 2019-08-20 | 深圳宾德生物技术有限公司 | 一种靶向性抗肿瘤t细胞及其制备方法和应用 |
| JP7273421B2 (ja) | 2018-02-21 | 2023-05-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 |
| CN112105382A (zh) | 2018-02-23 | 2020-12-18 | 恩多塞特公司 | 用于car t细胞疗法的顺序方法 |
| CN108440674A (zh) * | 2018-04-28 | 2018-08-24 | 杭州荣泽生物科技有限公司 | 一种Trop-2特异性嵌合抗原受体细胞制备及其用途 |
| WO2019239213A2 (en) | 2018-06-01 | 2019-12-19 | Medicenna Therapeutics Inc. | Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof |
| WO2019232523A1 (en) | 2018-06-01 | 2019-12-05 | The Board Of Trustees Of The Leland Stanford Junior University | Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof |
| US12419954B2 (en) * | 2020-01-31 | 2025-09-23 | City Of Hope | Targeted chimeric antigen receptor modified T cells for treatment of IL13Rα2 positive malignancies |
| AU2021217003A1 (en) | 2020-02-04 | 2022-09-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Anti-dinitrophenol chimeric antigen receptors |
| WO2021241719A1 (ja) * | 2020-05-28 | 2021-12-02 | 中外製薬株式会社 | 改良されたグランザイムｂ改変体 |
| CA3193009A1 (en) * | 2020-08-26 | 2022-03-03 | The Regents Of The University Of California | Methods and compositions for treating glioblastoma |
| AU2021342299A1 (en) * | 2020-09-11 | 2023-04-13 | The United States Of America, As Represented By The Secretary Of Agriculture | Compositions and methods of use thereof for prevention and treatment of influenza infections |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| CN114907485B (zh) * | 2021-02-08 | 2024-04-26 | 浙江大学 | 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体 |
| CN113304267B (zh) * | 2021-06-11 | 2022-03-15 | 河南大学 | 肺癌的治疗靶点及其应用 |
| CN114014941B (zh) * | 2022-01-10 | 2022-04-12 | 卡瑞济(北京)生命科技有限公司 | 靶向IL13Rα2的嵌合抗原受体及其用途 |
| CN116549667B (zh) * | 2023-05-29 | 2024-02-09 | 四川普锐特药业有限公司 | 一种pas修饰的脂质纳米粒、包含其的药物制剂，及其制备方法和用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965126A (en) * | 1996-03-25 | 1999-10-12 | The Penn State Research Foundation | use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents |
| DE60038622D1 (de) * | 1999-10-20 | 2008-05-29 | Univ Johns Hopkins Med | Chimäre immunogene zusammensetzungen und dafür kodierende nukleinsäure |
| US20030235555A1 (en) * | 2002-04-05 | 2003-12-25 | David Shealey | Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses |
| IL163515A0 (en) * | 2002-03-01 | 2005-12-18 | Bristol Myers Squibb Co | Transgenic non-human mammals |
| US7709625B2 (en) * | 2004-06-10 | 2010-05-04 | The Board Of Regents Of The University Of Texas | Methods and compositions for bone marrow stem cell-derived macrophage delivery of genes for gene therapy |
| WO2007075077A1 (es) * | 2005-11-16 | 2007-07-05 | Universidad Nacional Autonoma De Mexico | Uso de agentes modificantes del transcriptoma más quimioterapia o radioterapia contra el cáncer |
| CN101616685B (zh) * | 2006-03-06 | 2013-07-24 | 阿穆尼克斯运营公司 | 非结构化重组聚合物和其应用 |
| US20080206139A1 (en) * | 2006-11-03 | 2008-08-28 | The Penn State Research Foundation | Delivery system for diagnostic and therapeutic agents |
| EP4032552B1 (en) * | 2008-08-26 | 2023-10-04 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| US9273283B2 (en) * | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| PT2552959T (pt) * | 2010-03-26 | 2017-04-21 | Memorial Sloan Kettering Cancer Center | Anticorpos para muc16 e métodos de utilização dos mesmos |
| WO2014090985A1 (en) * | 2012-12-13 | 2014-06-19 | Universität Leipzig | T-cell modulation by exon skipping |
| EP4303232A3 (en) * | 2013-02-15 | 2024-04-17 | The Regents of The University of California | Chimeric antigen receptor and methods of use thereof |
| EP2968601A1 (en) * | 2013-03-10 | 2016-01-20 | Baylor College Of Medicine | Chemotherapy-resistant immune cells |
| ES2792849T3 (es) * | 2014-02-10 | 2020-11-12 | Univ Emory | Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer |
| SG10202103475XA (en) | 2014-12-02 | 2021-05-28 | Prospect Chartercare Rwmc Llc | Methods and compositons for treating cancer |
-
2015
- 2015-12-01 SG SG10202103475XA patent/SG10202103475XA/en unknown
- 2015-12-01 WO PCT/US2015/063267 patent/WO2016089916A1/en not_active Ceased
- 2015-12-01 JP JP2017529284A patent/JP2017537622A/ja active Pending
- 2015-12-01 CN CN201580074883.3A patent/CN107709353A/zh active Pending
- 2015-12-01 MX MX2017007272A patent/MX2017007272A/es unknown
- 2015-12-01 EP EP15865800.5A patent/EP3227317A4/en not_active Withdrawn
- 2015-12-01 EA EA201791210A patent/EA201791210A1/ru unknown
- 2015-12-01 CA CA2969714A patent/CA2969714A1/en not_active Abandoned
- 2015-12-01 KR KR1020177018139A patent/KR20180041087A/ko not_active Withdrawn
- 2015-12-01 BR BR112017011771A patent/BR112017011771A2/pt not_active Application Discontinuation
- 2015-12-01 US US14/956,299 patent/US9650428B2/en not_active Expired - Fee Related
- 2015-12-01 HK HK18110565.4A patent/HK1251862A1/zh unknown
- 2015-12-01 SG SG11201704519YA patent/SG11201704519YA/en unknown
- 2015-12-01 AU AU2015355084A patent/AU2015355084A1/en not_active Abandoned
- 2015-12-02 AR ARP150103939A patent/AR102879A1/es unknown
- 2015-12-02 TW TW104140317A patent/TW201636425A/zh unknown
- 2015-12-02 UY UY0001036418A patent/UY36418A/es not_active Application Discontinuation
-
2017
- 2017-05-09 US US15/590,961 patent/US20180072789A1/en not_active Abandoned
- 2017-06-01 IL IL252610A patent/IL252610A0/en unknown
- 2017-06-02 PH PH12017501031A patent/PH12017501031A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537622A5 (2) | ||
| Heidbuechel et al. | Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies | |
| JP7574243B2 (ja) | 抗ｃｄ７０キメラ抗原受容体 | |
| JP2022109953A5 (2) | ||
| JP2022066290A (ja) | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 | |
| JP2025181929A (ja) | Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用 | |
| JP2018529380A5 (2) | ||
| JP2023139070A5 (2) | ||
| JP2017537627A5 (2) | ||
| JP2019535262A5 (2) | ||
| JP2018516092A5 (2) | ||
| JP2017538401A5 (2) | ||
| JP2020529841A5 (2) | ||
| JP2019500894A5 (2) | ||
| CN111886243A (zh) | 非-hla限制性t细胞受体及其用途 | |
| JP7566628B2 (ja) | キメラ抗原受容体を発現する免疫細胞 | |
| HRP20190472T1 (hr) | Klaudin-6 specifični imunoreceptori i t-stanični epitopi | |
| JP2018518459A5 (2) | ||
| JP2017500869A5 (2) | ||
| JP2016534717A5 (2) | ||
| JP2017526361A5 (2) | ||
| JP2016519068A5 (2) | ||
| JP2017529067A5 (2) | ||
| JP2018505139A5 (2) | ||
| CN108137670A (zh) | Ny-eso-1特异性tcr及其使用方法 |